Last reviewed · How we verify
Insulin Aspart 6 Day (6D)
Insulin Aspart 6 Day is a long-acting basal insulin analog designed to provide extended glucose control with a 6-day duration of action.
Insulin Aspart 6 Day is a long-acting basal insulin analog designed to provide extended glucose control with a 6-day duration of action. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Aspart 6 Day (6D) |
|---|---|
| Sponsor | Eli Lilly and Company |
| Drug class | Long-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Insulin Aspart 6D is a modified version of insulin aspart engineered to have a prolonged half-life and duration of action compared to standard insulin aspart. By extending the duration to approximately 6 days, it aims to provide more stable basal insulin coverage with less frequent dosing, potentially improving patient adherence and glycemic control in diabetes management.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Aspart 6 Day (6D) CI brief — competitive landscape report
- Insulin Aspart 6 Day (6D) updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI